secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2024-07-17T23:59:59+00:00
Accession:  0001437749-24-022876
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02, 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences CEO Remi Barbier resigns; Rick Barry named Executive Chairman; CEO search begins
--------------------------------------------------------------------------------

- CEO/President Remi Barbier resigns effective Sep 13, 2024; also resigns as Chairman and Board member immediately.
- SVP Neuroscience Lindsay Burns steps down; enters 1-year consulting agreement at $500/hour; receives $0.5M severance.
- Independent director Rick Barry appointed Executive Chairman and principal executive officer; CEO search launched.
- Board adds Pierre Gravier as Audit Committee Chair, Robert Anderson as Nominating & Governance Committee Chair.
- Company pledges enhanced transparency: quarterly analyst calls and timely posting of Phase 3 trial results to clinicaltrials.gov.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774924022876/0001437749-24-022876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774924022876/sava20240717_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-022876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer